Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2016 | What are the predictors of ponatinib treatment response?

Michael Mauro • 9 Dec 2016
ASH 2016
Chronic Myeloid Leukemia Ponatinib

Michael J. Mauro, MD from the Memorial Sloan Kettering Cancer Center, New York, NY discusses his talk on predictors of ponatinib treatment response at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA. Dr Mauro gives an overview of his study, which considered different characteristics of chronic myeloid leukemia (CML) patients receiving ponatinib treatment, to identify treatment outcome predictors. Preliminary data analysis was presented during ASH, including some factors that may predict for success of ponatinib therapy, such as mutation status, demographic and disease biology. This video has been supported by Incyte through an unrestricted educational grant.

More from Michael Mauro

6:31
An overview of trials investigating asciminib in the treatment of Ph+ CML
Michael Mauro • 18 Dec 2023
2:26
ASCEMBL: asciminib versus bosutinib in third-line treatment of CP-CML
Michael Mauro • 18 Dec 2023
1:14
Unmet needs in pediatric CML
Michael Mauro • 22 Oct 2022
1:52
ESH CML session highlights: pediatrics, biomarkers, and COVID
Michael Mauro • 22 Oct 2022

Related Videos

1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
2:02
Optimizing myeloablative conditioning with precision-engineered Orca-T in older patients
Caspian Oliai • 10 Dec 2023
3:21
A Phase I trial of Hu8F4, an anti-PR1/HLA-A2 monoclonal antibody, in R/R myeloid malignancies
Tapan Kadia • 14 Dec 2023
6:31
An overview of trials investigating asciminib in the treatment of Ph+ CML
Michael Mauro • 18 Dec 2023
The content of VJHemOnc is intended for healthcare professionals